Characteristic (%) | MSD (n = 961) | UD (n = 593) | p value |
---|---|---|---|
Median follow-up, months | 30 (1–157) | 27 (1–137) | 0.28 |
Median age, years (range) | 49 (18–75) | 52 (18–77) | <0.01 |
Median year of HSCT (range) | 2006 (2000–2012) | 2009 (2000–2012) | <0.01 |
Interval from diagnosis to HSCT, months (range) | 8.6 (2–155) | 10.3 (2.5–186) | <0.01 |
De novo AML | 836 (87) | 480 (81) | <0.01 |
sAML | 125 (13) | 113 (19) | |
Prior auto-HSCT | 57 (6) | 41 (7) | 0.59 |
Donor’s gender | |||
Male | 500 (52) | 417 (72) | <0.01 |
Female | 452 (48) | 162 (28) | |
CMV positive serostatus | <0.01 | ||
Patient | 472 (69) | 210 (37) | |
Donor | 417 (62) | 244 (42) | |
Conditioning regimen | |||
MAC | 559 (60) | 269 (46) | <0.01 |
RIC | 365 (40) | 316 (54) | |
Conditioning details | |||
BuCy | 155 (16) | 81 (14) | <0.01 |
BuFlu | 135 (14) | 112 (19) | |
FluMel | 89 (9) | 81 (14) | |
Threo-based | 36 (4) | 26 (4) | |
MAC TBI | 178 (1) | 79 (13) | |
RIC TBI | 32 (3) | 13 (2) | |
Other | 336 (35) | 201 (34) | |
Stem cell source | |||
BM | 107 (11) | 60 (10) | 0.14 |
PBSC | 854 (89) | 533 (90) | |
GVHD prophylaxis | |||
CsA alone | 115 (12) | 81 (14) | <0.01 |
CsA + MMF | 182 (19) | 187 (31) | |
CsA + MTX | 362 (38) | 246 (41) | |
Other | 68 (7) | 75 (13) | |
Missing | 234 (24) | 4 (1) | |
In vivo TCD | <0.01 | ||
ATG | 167 (17) | 388 (65) | |
Alemtuzumab | 20 (2) | 47 (8) | |
No | 521 (54) | 154 (26) | |
Missing | 235 (24) | 4 (1) |